A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yi, Jun Ho | - |
dc.contributor.author | Kang, Jung Hun | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Baek, Hyun Jin | - |
dc.contributor.author | Lee, Soon Il | - |
dc.contributor.author | Lim, Do Hyoung | - |
dc.contributor.author | Won, Young-Woong | - |
dc.contributor.author | Ji, Jun Ho | - |
dc.contributor.author | Kim, Hyo Song | - |
dc.contributor.author | Rha, Sun Young | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Lee, Kyung Eun | - |
dc.contributor.author | Lim, Taekyu | - |
dc.contributor.author | Maeng, Chi Hoon | - |
dc.contributor.author | Kim, Moon Jin | - |
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Park, Joon Oh | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Kang, Won Ki | - |
dc.contributor.author | Park, Se Hoon | - |
dc.date.available | 2020-02-28T02:43:17Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8435 | - |
dc.description.abstract | Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11(6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The mediari progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.subject | S-1 PLUS CISPLATIN | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | 1ST-LINE THERAPY | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | COMBINATION | - |
dc.subject | FLUOROURACIL | - |
dc.subject | CAPECITABINE | - |
dc.subject | OXALIPLATIN | - |
dc.title | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000374197200015 | - |
dc.identifier.doi | 10.4143/crt.2015.155 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.48, no.2, pp.553 - 560 | - |
dc.identifier.kciid | ART002099170 | - |
dc.identifier.scopusid | 2-s2.0-84963894352 | - |
dc.citation.endPage | 560 | - |
dc.citation.startPage | 553 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 48 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Stomach neoplasms | - |
dc.subject.keywordAuthor | ErbB-2 receptor | - |
dc.subject.keywordAuthor | Trastuzumab | - |
dc.subject.keywordAuthor | Histology | - |
dc.subject.keywordAuthor | Ethnic groups | - |
dc.subject.keywordPlus | S-1 PLUS CISPLATIN | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | 1ST-LINE THERAPY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.